167 related articles for article (PubMed ID: 30267820)
1. TRIP13 is a predictor for poor prognosis and regulates cell proliferation, migration and invasion in prostate cancer.
Dong L; Ding H; Li Y; Xue D; Li Z; Liu Y; Zhang T; Zhou J; Wang P
Int J Biol Macromol; 2019 Jan; 121():200-206. PubMed ID: 30267820
[TBL] [Abstract][Full Text] [Related]
2. Thyroid Receptor-Interacting Protein 13 is Correlated with Progression and Poor Prognosis in Bladder Cancer.
Niu L; Gao Z; Cui Y; Yang X; Li H
Med Sci Monit; 2019 Sep; 25():6660-6668. PubMed ID: 31486418
[TBL] [Abstract][Full Text] [Related]
3. TRIP13 promotes tumor growth and is associated with poor prognosis in colorectal cancer.
Sheng N; Yan L; Wu K; You W; Gong J; Hu L; Tan G; Chen H; Wang Z
Cell Death Dis; 2018 Mar; 9(3):402. PubMed ID: 29540729
[TBL] [Abstract][Full Text] [Related]
4. MiR-515-5p acts as a tumor suppressor via targeting TRIP13 in prostate cancer.
Zhang X; Zhou J; Xue D; Li Z; Liu Y; Dong L
Int J Biol Macromol; 2019 May; 129():227-232. PubMed ID: 30685303
[TBL] [Abstract][Full Text] [Related]
5. Upregulation of thyroid hormone receptor interactor 13 is associated with human hepatocellular carcinoma.
Ju L; Li X; Shao J; Lu R; Wang Y; Bian Z
Oncol Rep; 2018 Dec; 40(6):3794-3802. PubMed ID: 30542731
[TBL] [Abstract][Full Text] [Related]
6. TRIP13 promotes the proliferation and invasion of lung cancer cells via the Wnt signaling pathway and epithelial-mesenchymal transition.
Li ZH; Lei L; Fei LR; Huang WJ; Zheng YW; Yang MQ; Wang Z; Liu CC; Xu HT
J Mol Histol; 2021 Feb; 52(1):11-20. PubMed ID: 33128167
[TBL] [Abstract][Full Text] [Related]
7. Elevated TRIP13 drives the AKT/mTOR pathway to induce the progression of hepatocellular carcinoma via interacting with ACTN4.
Zhu MX; Wei CY; Zhang PF; Gao DM; Chen J; Zhao Y; Dong SS; Liu BB
J Exp Clin Cancer Res; 2019 Sep; 38(1):409. PubMed ID: 31533816
[TBL] [Abstract][Full Text] [Related]
8. Thyroid hormone receptor interactor 13 (TRIP13) overexpression associated with tumor progression and poor prognosis in lung adenocarcinoma.
Li W; Zhang G; Li X; Wang X; Li Q; Hong L; Shen Y; Zhao C; Gong X; Chen Y; Zhou J
Biochem Biophys Res Commun; 2018 May; 499(3):416-424. PubMed ID: 29567476
[TBL] [Abstract][Full Text] [Related]
9. TRIP13 interference inhibits the proliferation and metastasis of thyroid cancer cells through regulating TTC5/p53 pathway and epithelial-mesenchymal transition related genes expression.
Yu L; Xiao Y; Zhou X; Wang J; Chen S; Peng T; Zhu X
Biomed Pharmacother; 2019 Dec; 120():109508. PubMed ID: 31648166
[TBL] [Abstract][Full Text] [Related]
10. Upregulation of TRIP13 promotes the malignant progression of lung cancer via the EMT pathway.
Lu R; Zhou Q; Ju L; Chen L; Wang F; Shao J
Oncol Rep; 2021 Aug; 46(2):. PubMed ID: 34184074
[TBL] [Abstract][Full Text] [Related]
11. Increased expression of TRIP13 drives the tumorigenesis of bladder cancer in association with the EGFR signaling pathway.
Gao Y; Liu S; Guo Q; Zhang S; Zhao Y; Wang H; Li T; Gong Y; Wang Y; Zhang T; Dong Z; Bacich D; Chowdhury WH; Rodriguez R; Wang Z
Int J Biol Sci; 2019; 15(7):1488-1499. PubMed ID: 31337978
[TBL] [Abstract][Full Text] [Related]
12. TRIP13 promotes proliferation and invasion of epithelial ovarian cancer cells through Notch signaling pathway.
Zhou XY; Shu XM
Eur Rev Med Pharmacol Sci; 2019 Jan; 23(2):522-529. PubMed ID: 30720159
[TBL] [Abstract][Full Text] [Related]
13. Loss of thyroid hormone receptor interactor 13 inhibits cell proliferation and survival in human chronic lymphocytic leukemia.
Zhou K; Zhang W; Zhang Q; Gui R; Zhao H; Chai X; Li Y; Wei X; Song Y
Oncotarget; 2017 Apr; 8(15):25469-25481. PubMed ID: 28424416
[TBL] [Abstract][Full Text] [Related]
14. TRIP13 promotes lung cancer cell growth and metastasis through AKT/mTORC1/c-Myc signaling.
Cai W; Ni W; Jin Y; Li Y
Cancer Biomark; 2021; 30(2):237-248. PubMed ID: 33136091
[TBL] [Abstract][Full Text] [Related]
15. HMGA1-TRIP13 axis promotes stemness and epithelial mesenchymal transition of perihilar cholangiocarcinoma in a positive feedback loop dependent on c-Myc.
Li Z; Liu J; Chen T; Sun R; Liu Z; Qiu B; Xu Y; Zhang Z
J Exp Clin Cancer Res; 2021 Mar; 40(1):86. PubMed ID: 33648560
[TBL] [Abstract][Full Text] [Related]
16. TRIP13 promotes the cell proliferation, migration and invasion of glioblastoma through the FBXW7/c-MYC axis.
Zhang G; Zhu Q; Fu G; Hou J; Hu X; Cao J; Peng W; Wang X; Chen F; Cui H
Br J Cancer; 2019 Dec; 121(12):1069-1078. PubMed ID: 31740732
[TBL] [Abstract][Full Text] [Related]
17. TRIP13 promotes metastasis of colorectal cancer regardless of p53 and microsatellite instability status.
Agarwal S; Behring M; Kim HG; Chandrashekar DS; Chakravarthi BVSK; Gupta N; Bajpai P; Elkholy A; Al Diffalha S; Datta PK; Heslin MJ; Varambally S; Manne U
Mol Oncol; 2020 Dec; 14(12):3007-3029. PubMed ID: 33037736
[TBL] [Abstract][Full Text] [Related]
18. TRIP13 impairs mitotic checkpoint surveillance and is associated with poor prognosis in multiple myeloma.
Tao Y; Yang G; Yang H; Song D; Hu L; Xie B; Wang H; Gao L; Gao M; Xu H; Xu Z; Wu X; Zhang Y; Zhu W; Zhan F; Shi J
Oncotarget; 2017 Apr; 8(16):26718-26731. PubMed ID: 28157697
[TBL] [Abstract][Full Text] [Related]
19. LncRNA TINCR is associated with clinical progression and serves as tumor suppressive role in prostate cancer.
Dong L; Ding H; Li Y; Xue D; Liu Y
Cancer Manag Res; 2018; 10():2799-2807. PubMed ID: 30154672
[TBL] [Abstract][Full Text] [Related]
20. SNORA42 enhances prostate cancer cell viability, migration and EMT and is correlated with prostate cancer poor prognosis.
Yi C; Wan X; Zhang Y; Fu F; Zhao C; Qin R; Wu H; Li Y; Huang Y
Int J Biochem Cell Biol; 2018 Sep; 102():138-150. PubMed ID: 30053504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
